These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35251494)

  • 21. [Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].
    Minucci A; Mazzuccato G; Marchetti C; Pietragalla A; Scambia G; Fagotti A; Urbani A
    Mol Biol (Mosk); 2020; 54(4):688-698. PubMed ID: 32840490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.
    Feliubadaló L; Lopez-Doriga A; Castellsagué E; del Valle J; Menéndez M; Tornero E; Montes E; Cuesta R; Gómez C; Campos O; Pineda M; González S; Moreno V; Brunet J; Blanco I; Serra E; Capellá G; Lázaro C
    Eur J Hum Genet; 2013 Aug; 21(8):864-70. PubMed ID: 23249957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
    Castéra L; Krieger S; Rousselin A; Legros A; Baumann JJ; Bruet O; Brault B; Fouillet R; Goardon N; Letac O; Baert-Desurmont S; Tinat J; Bera O; Dugast C; Berthet P; Polycarpe F; Layet V; Hardouin A; Frébourg T; Vaur D
    Eur J Hum Genet; 2014 Nov; 22(11):1305-13. PubMed ID: 24549055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.
    Lou SK; Grenier S; Care M; McCuaig J; Stockley TL; Clarke B; Ruff HM; Boerner SL
    Cancer Cytopathol; 2021 Nov; 129(11):907-913. PubMed ID: 34157791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The molecular analysis of BRCA1 and BRCA2: Next-generation sequencing supersedes conventional approaches.
    D'Argenio V; Esposito MV; Telese A; Precone V; Starnone F; Nunziato M; Cantiello P; Iorio M; Evangelista E; D'Aiuto M; Calabrese A; Frisso G; D'Aiuto G; Salvatore F
    Clin Chim Acta; 2015 Jun; 446():221-5. PubMed ID: 25896959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
    Endris V; Stenzinger A; Pfarr N; Penzel R; Möbs M; Lenze D; Darb-Esfahani S; Hummel M; Sabine-Merkelbach-Bruse ; Jung A; Lehmann U; Kreipe H; Kirchner T; Büttner R; Jochum W; Höfler G; Dietel M; Weichert W; Schirmacher P
    Virchows Arch; 2016 Jun; 468(6):697-705. PubMed ID: 27003155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model.
    Tarabeux J; Zeitouni B; Moncoutier V; Tenreiro H; Abidallah K; Lair S; Legoix-Né P; Leroy Q; Rouleau E; Golmard L; Barillot E; Stern MH; Rio-Frio T; Stoppa-Lyonnet D; Houdayer C
    Eur J Hum Genet; 2014 Apr; 22(4):535-41. PubMed ID: 23942203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of false positive mutations in BRCA gene by next generation sequencing.
    Suryavanshi M; Kumar D; Panigrahi MK; Chowdhary M; Mehta A
    Fam Cancer; 2017 Jul; 16(3):311-317. PubMed ID: 27848044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of
    Concolino P; Capoluongo E
    Expert Rev Mol Diagn; 2019 Sep; 19(9):795-802. PubMed ID: 31429350
    [No Abstract]   [Full Text] [Related]  

  • 37. Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory.
    Strom CM; Rivera S; Elzinga C; Angeloni T; Rosenthal SH; Goos-Root D; Siaw M; Platt J; Braastadt C; Cheng L; Ross D; Sun W
    PLoS One; 2015; 10(8):e0136419. PubMed ID: 26295337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Reference System for BRCA Mutation Detection Based on Next-Generation Sequencing in the Chinese Population.
    Qu S; Chen Q; Yi Y; Shao K; Zhang W; Wang Y; Bai J; Li X; Liu Z; Wang X; Jing R; Guan Y; Yi X; Yan M; Cao B; Chen F; Zhu S; Yang X; Wu Y; Huang J
    J Mol Diagn; 2019 Jul; 21(4):677-686. PubMed ID: 31026599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.